FDA accepts Pfizer-Sanofi application for insulin inhaler

03/4/2005 | Wall Street Journal, The

Pfizer and Sanofi-Aventis, partners in developing a form of insulin that is inhaled, said the U.S. FDA accepted its application and will review the product, called Exubera, which delivers the insulin in a dry-powder form. The companies plan to co-market the inhaler for adults with Type 1 and Type 2 diabetes, making it the first form of insulin given by means other than an injection or a pump. San Carlos, Calif.-based Nektar Therapeutics developed both the inhaler and the dry form of insulin.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Food & Drug Associate
Confidential
Washington, D.C., DC